Klonetics Plant Science Inc. Receives Nursery Cultivation License from Health Canada
2.1 min readPublished On: June 8th, 2021By News Team
KELOWNA, B.C.– Klonetics Plant Science Inc announced they received its Health Canada Nursery Cultivation licence to produce cannabis starting materials available for sale to the cannabis industry in Canada. Its impressive 25,000 Square Foot state of the art facility in Kelowna will produce Ready to Flower plants at an industrial scale, providing 2.8 million ready to flower plants to the market annually and with capacity to reach over 4 million by 2022.
Klonetics’ cutting edge tissue culture technology combined with industry leading Canadian scientists, allows for the production of consistent and reliable cannabis plants that are certified to be free of viruses, viroids, fungus and bacteria. This provides Klonetics customers with the strongest foundation to assist in generating the highest quality flower. Klonetics has significantly invested in the future of cannabis science by working with top scientists including; Dr. Timothy Sharbel as Chief Scientist, Dr. Krin Mann as Chief Tissue Culture Scientist, and Dr. Marco Pellino as Research Manager. Through partnerships with the University of Saskatchewan, the University of British Columbia Okangan, Genome Prairie Canada and the National Research Council, Klonetics is strongly positioned to make significant advancements in cannabis breeding, genomic analysis, and research and development.
Klonetics also has the largest breeder-backed catalogue of cannabis cultivars in the world available to licensed producers and micro-cultivators. This Provides the opportunity for cultivators to access industry sought-after genetics delivered to their doors as well as access to breeders, facilitating productive long-term relationships.
Bringing Ready to Flower plants to the industry will help licensed producers increase their revenue by up to 30% by removing the need for mothering and cloning rooms and only growing flowering plants. Additionally, most licensed producers will be able to add additional grow cycles to their annual production by using Klonetics Ready to Flower plants.
David Brough, CEO of Klonetics commented:
“I am extremely proud of our team and I would like to thank them for their unwavering dedication to achieve this significant milestone. With the license in hand we now have the critical tool we needed to execute our vision. We have scoured the globe to partner with some of the most influential cannabis breeders. Our exclusive and certified breeder backed genetics catalogue brings the icons of the industry and their creations into one incredible collaboration. We are diligently working with our talented science team to unlock the catalogues true potential. We look forward to our role in improving profitability and efficiency in the cannabis industry in Canada and abroad.”
Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.
TORONTO - Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, announced today the launch of Peppermint Phatty 510 vape, the newest addition to the Good Supply vape ...
TALLAHASSEE, Fla. - Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), announced the official launch of Khalifa Kush premium medical marijuana products statewide in all Trulieve Branded Pennsylvania retail locations starting Monday, December 12, 2022. This ...
DISCLAIMER NOTE: This email should be considered strictly private and confidential. Sender of this email is not a United States Securities Dealer, nor Broker, nor U.S. Investment Adviser. Sender is a Registered Corporation and Consultant, and makes no warranties, nor representations as to the buyer, seller, or transaction. Furthermore, this email includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Read more